Site Loader

Author information Article notes Copyright and License information Disclaimer Betahistine dihydrochloride (Serc) is an oral preparation of a. PACKAGE LEAFLET: INFORMATION FOR THE USER. Betahistine Dihydrochloride 8 mg Tablets. Betahistine Dihydrochloride 16 mg Tablets prescription. Betahistine is an antivertigo drug first used for treating vertigo assosicated with Ménière’s disease. It is also commonly Generic Prescription Products. Show.

Author: Arajar Nataur
Country: Samoa
Language: English (Spanish)
Genre: Medical
Published (Last): 19 February 2012
Pages: 149
PDF File Size: 13.5 Mb
ePub File Size: 16.27 Mb
ISBN: 678-2-43487-228-6
Downloads: 21785
Price: Free* [*Free Regsitration Required]
Uploader: Bagul

Nizatidine The therapeutic efficacy of Betahistine can be decreased when used in combination with Nizatidine. The therapeutic efficacy of Betahistine can be decreased when used in combination with Dexchlorpheniramine maleate.

Also contraindicated are the following: Selegiline The metabolism pgescribing Betahistine can be decreased when combined with Selegiline. Unusual presentations of acoustic tumours. Chlorprothixene The therapeutic efficacy of Betahistine can be decreased when used in combination with Chlorprothixene.

Asenapine The therapeutic efficacy of Betahistine can be decreased when used in combination with Asenapine. Betahistine also acts as a histamine H3-receptor antagonist which causes an increased output of histamine from histaminergic ijformation endings which can further increase the direct H1-agonist activity.

Betahistine

Pirbuterol The therapeutic efficacy of Pirbuterol can be decreased when used in combination with Betahistine. The therapeutic efficacy of Betahistine can be decreased when used in combination with Cyclizine. The therapeutic efficacy of Betahistine can prescriibng decreased when used in combination with Dimetotiazine. Phenelzine The metabolism of Betahistine can be decreased when combined with Phenelzine.

Betahistine – DrugBank

To date the most reliable data we have available regarding the prevalence of Meniere’s disease in the UK are from Metiamide The therapeutic efficacy of Betahistine can be decreased when used in combination with Metiamide. The therapeutic efficacy of Betahistine can be decreased when used in combination with Terfenadine.

  3RU1136 4EB0 PDF

prescribig

The therapeutic efficacy of Fenoterol can be decreased when used in combination with Betahistine. J Pharmacol Exp Ther. The therapeutic efficacy of Betahistine can be decreased when used in combination with Levocetirizine.

The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Betahistine. The therapeutic efficacy of Betahistine can be decreased when used in combination with Phenindamine.

The therapeutic efficacy of Betahistine can be decreased when used in combination with Dexchlorpheniramine. The therapeutic efficacy of Betahistine can be decreased when used in combination with Methantheline.

Prescdibing therapeutic efficacy of Betahistine can be decreased when used in combination with Bamipine. Ziprasidone The therapeutic efficacy of Betahistine can be decreased when used in combination with Ziprasidone.

Each tablet contains Incormation dihydrochloride 8 mg Excipient s with known effect: Any unused product or waste material should be disposed of in accordance with local requirements. Daily dose should not exceed 48 mg. Trimipramine The therapeutic efficacy of Betahistine can be decreased when used in combination with Trimipramine.

The increased amounts of histamine released from histaminergic nerve endings stimulates H 1 receptors, thus augmenting the direct agonistic effects of betahistine on these receptors. PF The therapeutic efficacy of PF can be decreased when used in combination with Betahistine. Furazolidone The metabolism of Betahistine can be decreased when combined with Furazolidone. The mechanism of action of betahistine is known partially. The therapeutic efficacy of Betahistine can be decreased when used in combination with Benzquinamide.

Rupatadine The therapeutic efficacy of Betahistine can be decreased when used in combination with Rupatadine. Isoetarine The therapeutic efficacy of Isoetarine can be decreased when used in combination with Betahistine. Therefore, the assessment of the pharmacokinetics of betahistine is based on the plasma concentration data of the only metabolite 2-pyridylacetic acid.

  BIOKEMI AF VIBEKE DINESS BORUP PDF

Brompheniramine The therapeutic efficacy of Betahistine can be decreased when used in combination with Brompheniramine. Mephentermine Mephentermine may decrease the sedative and stimulatory activities of Betahistine. Fenoterol The therapeutic efficacy of Fenoterol can be decreased when used in combination with Betahistine. Dexchlorpheniramine maleate The therapeutic efficacy of Betahistine can be decreased when used in combination ptescribing Dexchlorpheniramine maleate. Despite a confident diagnosis of Meniere’s disease, a pharmacological treatment remains elusive, particularly because the underlying pathophysiology of this condition remains to be proven.

Bamipine The therapeutic efficacy of Betahistine can be decreased when used in combination with Bamipine. The therapeutic rpescribing of Betahistine can be decreased when used in combination with Isothipendyl. Doxepin The therapeutic efficacy of Betahistine can be decreased when used in combination with Doxepin.

Mianserin The therapeutic efficacy of Betahistine can be decreased when used in combination with Mianserin.

Prescribing practices for Betahistine

Oxatomide The therapeutic efficacy of Betahistine can be decreased when used in combination with Oxatomide. Betahistine is metabolized primarily into 2-pyridylacetic acid and is subsequently excreted in the urine.

The therapeutic efficacy of Betahistine can be decreased when used in combination with Cimetidine. The therapeutic efficacy of Betahistine can be decreased when used in combination with Metiamide.